Home > Institute Collections > BN DZNE > BN DZNE-LIS > Elevated α-Synuclein Aggregate Levels in the Urine of Patients with Isolated REM Sleep Behavior Disorder and Parkinson's Disease. > print

001     283132
005     20260105112800.0
024 7 _ |a 10.1002/ana.27250
|2 doi
024 7 _ |a pmid:40285625
|2 pmid
024 7 _ |a pmc:PMC12174725
|2 pmc
024 7 _ |a 0364-5134
|2 ISSN
024 7 _ |a 1531-8249
|2 ISSN
037 _ _ |a DZNE-2026-00028
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Müller, Laura
|b 0
245 _ _ |a Elevated α-Synuclein Aggregate Levels in the Urine of Patients with Isolated REM Sleep Behavior Disorder and Parkinson's Disease.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1767608833_32744
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Parkinson's disease (PD) is a neurodegenerative disorder characterized by α-synuclein aggregation in neurons. Recent advances suggest α-synuclein aggregates could serve as a biomarker for PD and related synucleinopathies. This study used surface-based fluorescence intensity distribution analysis (sFIDA) to measure α-synuclein aggregates in urine. Patients with PD and isolated rapid eye movement sleep behavior disorder, a precursor to PD, had elevated concentrations compared with healthy controls. Sensitivity and specificity were 83% and 65% for PD versus controls and 89% and 62% for isolated rapid eye movement sleep behavior disorder versus controls. The findings highlight sFIDA's potential for diagnosing synucleinopathies. ANN NEUROL 2025;98:147-151.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: urine
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnosis
|2 MeSH
650 _ 2 |a REM Sleep Behavior Disorder: urine
|2 MeSH
650 _ 2 |a REM Sleep Behavior Disorder: diagnosis
|2 MeSH
650 _ 2 |a alpha-Synuclein: urine
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers: urine
|2 MeSH
650 _ 2 |a Sensitivity and Specificity
|2 MeSH
700 1 _ |a Özdüzenciler, Pelin
|b 1
700 1 _ |a Schedlich-Teufer, Charlotte
|b 2
700 1 _ |a Seger, Aline
|b 3
700 1 _ |a Jergas, Hannah
|0 0000-0003-3041-1583
|b 4
700 1 _ |a Fink, Gereon R
|0 0000-0002-8230-1856
|b 5
700 1 _ |a Willbold, Dieter
|b 6
700 1 _ |a Sommerauer, Michael
|0 P:(DE-2719)9003277
|b 7
|u dzne
700 1 _ |a Barbe, Michael T
|b 8
700 1 _ |a Tamgüney, Gültekin
|0 P:(DE-2719)2810376
|b 9
773 _ _ |a 10.1002/ana.27250
|g Vol. 98, no. 1, p. 147 - 151
|0 PERI:(DE-600)2037912-2
|n 1
|p 147 - 151
|t Annals of neurology
|v 98
|y 2025
|x 0364-5134
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)9003277
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN NEUROL : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ANN NEUROL : 2022
|d 2024-12-18
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1040260
980 1 _ |a EXTERN4VITA

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21